...
首页> 外文期刊>Biochimica et biophysica acta. Biomembranes >Kinetic analysis of the inhibition of the drug efflux protein AcrB using surface plasmon resonance
【24h】

Kinetic analysis of the inhibition of the drug efflux protein AcrB using surface plasmon resonance

机译:用表面等离子体共振抑制药物流出蛋白ACRB的动力学分析

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Multidrug efflux protein complexes such as AcrAB-TolC fromEscherichia coliare paramount in multidrug resistance in Gram-negative bacteria and are also implicated in other processes such as virulence and biofilm formation. Hence efflux pump inhibition, as a means to reverse antimicrobial resistance in clinically relevant pathogens, has gained increased momentum over the past two decades. Significant advances in the structural and functional analysis of AcrB have informed the selection of efflux pump inhibitors (EPIs). However, an accurate method to determine the kinetics of efflux pump inhibition was lacking. In this study we standardised and optimised surface plasmon resonance (SPR) to probe the binding kinetics of substrates and inhibitors to AcrB. The SPR method was also combined with a fluorescence drug binding method by which affinity of two fluorescent AcrB substrates were determined using the same conditions and controls as for SPR. Comparison of the results from the fluorescent assay to those of the SPR assay showed excellent correlation and provided validation for the methods and conditions used for SPR. The kinetic parameters of substrate (doxorubicin, novobiocin and minocycline) binding to AcrB were subsequently determined. Lastly, the kinetics of inhibition of AcrB were probed for two established inhibitors (phenylalanine arginyl β-naphthylamide and 1-1-naphthylmethyl-piperazine) and three novel EPIs: 4-isobutoxy-2-naphthamide (A2), 4-isopentyloxy-2-naphthamide (A3) and 4-benzyloxy-2-naphthamide (A9) have also been probed. The kinetic data obtained could be correlated with inhibitor efficacy and mechanism of action. This study is the first step in the quantitative analysis of the kinetics of inhibition of the clinically important RND-class of multidrug efflux pumps and will allow the design of improved and more potent inhibitors of drug efflux pumps. This article is part of a Special Issue entitled: Beyond the Structure-Function Horizon of Membrane Proteins edited by Ute Hellmich, Rupak Doshi and Benjamin McIlwain.
机译:多药渗透蛋白复合物,如传感来自革兰阴性细菌的多药抗性的ACRAB-TORCFESCHERICHIA COLIAOR,并且还涉及其他方法,例如毒力和生物膜形成。因此,由于临床相关病原体在临床相关病原体中逆转抗微生物抗性的手段,因此在过去的二十年中增加了势头的手段。 ACRB结构和功能分析的显着进展情况通知了Efflux泵抑制剂(EPIS)的选择。然而,缺乏准确的方法来确定流出泵抑制的动力学的方法。在这项研究中,我们标准化和优化的表面等离子体共振(SPR)以探测基质的结合动力学和抑制剂到ACRB。 SPR方法还与荧光药物结合方法组合,使用与SPR相同的条件和对照测定两个荧光ACRB基材的亲和力。荧光测定结果与SPR测定的结果的比较显示出优异的相关性,并提供了用于SPR的方法和条件的验证。随后测定与ACRB结合的底物(多柔比蛋白,Novociocin和minoCincin)的动力学参数。最后,探测ACRB的抑制动力学对两个已建立的抑制剂(苯丙氨酸氨基氨基β-萘甲酰和1-1-萘基甲基 - 哌嗪)和三种新的epis:4-异丁氧基-2-萘酰胺(A2),4-异戊基氧基-2 - 还探测了萘酰胺(A3)和4-苄氧基-2-萘酰胺(A9)。获得的动力学数据可以与抑制剂功效和作用机制相关。本研究是对临床重要性RND级泵的抑制动力学进行定量分析的第一步,并将允许设计改进和更有效的药物流出泵抑制剂。本文是题为特殊问题的一部分:超越由Ute Hellmich,Rupak Doshi和Benjamin McIlwain编辑的膜蛋白的结构功能视线。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号